Influenza
Conditions
Keywords
Influenza, Healthy, Immunogenicity, Elderly, Safety, Adults
Brief summary
The purpose of this study is to assess the immunogenicity and safety of GSK Biologicals' trivalent influenza vaccine manufactured for the 2012/2013 influenza season administered in adults (18 to 60 years) and in elderly (over 60 years).
Interventions
BIOLOGICALFluarix/Influsplit SSW 2012-2013
1 dose administered intramuscularly (or deeply subcutaneously) in the deltoid region of the non-dominant arm
Sponsors
GlaxoSmithKline
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Subjects who the investigator believes can and will comply with the requirements of the protocol. * A male or female aged 18 years or above at the time of vaccination. * Written informed consent obtained from the subject. * Healthy subjects or subjects with well-controlled chronic diseases as established by medical history and clinical examination before entering the study. * Female subjects of non-childbearing potential may be enrolled in the study. * Female subjects of childbearing potential may be enrolled in the study, if the subject: * has practiced adequate contraception for 30 days prior to vaccination, and * has a negative pregnancy test on the day of vaccination, and * has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of vaccination.
Exclusion criteria
* Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the dose of study vaccine, or planned use during the study period. * Chronic administration of immunosuppressants or other immune-modifying drugs within the six months prior to vaccination. Inhaled and topical steroids are allowed. * Administration of immunoglobulins and/or any blood products within the three months preceding the administration of the study vaccine or planned administration during the study period. * Administration of an influenza vaccine within the six months preceding the study vaccination. * Planned administration/ administration of a vaccine other than the study vaccine within 30 days before study vaccination and during the entire study period. * Clinically or virologically confirmed influenza infection within the six months preceding the study vaccination. * Acute disease and/or fever at the time of enrolment. * Acute, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests. * Chronic underlying disease, not stabilized or clinically serious. * History of chronic alcohol consumption and/or drug abuse. * Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. * History of Guillain-Barré syndrome. * History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. * Anaphylaxis following the administration of vaccine(s). * Pregnant or lactating female. * Female planning to become pregnant or planning to discontinue contraceptive precautions. * Any condition which, in the opinion of the investigator, prevents the subject from participating in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Humoral Immune Response in Terms of Haemagglutination (HA) Antibody Titers Against Each of the Three Vaccine Influenza Strains | At Day 0 and Day 21 | Antibody titers were expressed as Geometric mean titers (GMTs). The vaccine strains assessed were Flu A/Christchurch/16/10 (H1N1), Flu A/Victoria/361/11 (H3N2) and Flu B/Hubei-Wujiagang/158/09 (Yamagata). |
| Number of Subjects Who Were Seroprotected for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | At Day 0 and Day 21 | Seroprotection rate (SPR) was defined as the number of vaccinees with serum haemagglutination inhibition (HI) titer greater than or equal to (≥) 1:40. |
| Number of Seroconverted Subjects for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | At Day 21 | A seroconverted subjects was defined as a vaccinee with either a pre-vaccination titer less than (\<) 1:10 and a post-vaccination titer ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and at least a 4-fold increase in post-vaccination titer. |
| Mean Geometric Increase (MGI) for Haemagglutination Inhibition (HI) Antibody Titer Against Each of the Three Vaccine Influenza Strains. | At Day 21 | MGI was defined as the fold increase in serum HI GMT post-vaccination compared to Day 0. |
| Number of Subjects With Seroprotection Power (SPP) for HI Antibody Titer Against Each of the Three Vaccine Influenza Strains Above the Cut-off Value. | At Day 21 | SPP was defined as the number of vaccinees with a pre-vaccination titer \< 1:40 and a post-vaccination titer ≥ 1:40. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms. | During the 4-day (Day 0-Day 3) follow-up period after vaccination | Solicited local symptoms assessed were ecchymosis, induration, pain, redness and swelling. Any was defined as any solicited local symptom reported irrespective of intensity. Grade 3 pain was defined as pain that prevented normal everyday activities. Grade 3 ecchymosis, induration, redness and swelling was greater than 100 millimeters (mm) i.e. \>100mm. |
| Duration of Solicited General Symptoms. | During the 4-day follow-up period (Days 0-3) after vaccination | Duration was defined as number of days with any grade of general symptoms. |
| Humoral Immune Response in Terms of Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | At Day 0 and Day 21 | Antibody titers were expressed as Geometric mean titers (GMTs). The vaccine strains included H1N1, H3N2 and Yamagata antigens. The outcome measure was assessed by influenza vaccination status in the 2011-2012 season, in subjects aged greater than (\>) 60 years. |
| Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs). | During the 21-day follow-up period (Days 0-20) after vaccination | Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination. Grade 3 was an event that prevented normal activities and related was defined as an unsolicited AE assessed by the investigator to be causally related to the study vaccination. |
| Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) | During the entire study period (Days 0-21) | A serious adverse event was any untoward medical occurrence that: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination. |
| Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | During the 4-day follow-up period (Day 0-3) after vaccination | Solicited general symptoms assessed were arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, shivering, increased sweating and fever \[axillary temperature above 37.5 degrees Celsius (°C)\]. Gastrointestinal symptoms included nausea, vomiting, diarrhea and/or abdominal pain. Any = any solicited general symptom reported irrespective of intensity and relationship to vaccination. Related = symptoms considered by the investigator to have a causal relationship to vaccination. Grade 3 symptoms = symptoms that prevented normal activity. Grade 3 fever = axillary temperature above 39.0°C |
| Number of Subjects Who Were Seroprotected for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | At Day 0 and Day 21 | Seroprotection rate SPR was defined as the number of vaccinees with serum haemagglutination inhibition (HI) titer greater than or equal to (≥) 1:40. The outcome measure was assessed by the influenza vaccination status in the 2011-2012 season, in subjects aged \> 60 years. |
| Number of Subjects Who Seroconverted for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | At Day 21 | SCR was defined as the number of vaccinees with either a pre-vaccination titer less than (\<) 1:10 and a post-vaccination titer ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and at least 4-fold increase in post-vaccination titer. The outcome measure was assessed by influenza vaccination status in the 2011-2012 season, in subjects aged \> 60 years. |
| Mean Geometric Increase (MGI) for Haemagglutination Inhibition (HI) Antibody Titer Against Each of the Three Vaccine Influenza Strains. | At Day 21 | MGI was defined as the fold increase in serum HI GMT post-vaccination compared to Day 0. This outcome measure was assessed by influenza vaccination status in the 2011-2012 season, in subjects aged \> 60 years. |
| Duration of Solicited Local Symptoms. | During the 4-day follow-up period (Days 0-3) after vaccination | Duration was defined as number of days with any grade of local symptoms. |
Countries
Germany
Participant flow
Pre-assignment details
Approximately 50% of subjects in the Fluarix/Influsplit \> 60 Years Group and a maximum of 25% of subjects in the Fluarix/Influsplit 18-60 Years Group were allowed to have had a seasonal influenza vaccination the year before.
Participants by arm
| Arm | Count |
|---|---|
| Fluarix/Influsplit 18-60 Years Group Subjects 18-60 years of age received 1 dose of Fluarix/Influsplit SSW 2012-2013 vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm. | 60 |
| Fluarix/Influsplit > 60 Years Group Subjects above 60 years of age received 1 dose of Fluarix/Influsplit SSW 2012-2013 vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm. | 59 |
| Total | 119 |
Baseline characteristics
| Characteristic | Fluarix/Influsplit 18-60 Years Group | Fluarix/Influsplit > 60 Years Group | Total |
|---|---|---|---|
| Age, Continuous | 35.7 Years STANDARD_DEVIATION 11.98 | 70.3 Years STANDARD_DEVIATION 5.87 | 52.8 Years STANDARD_DEVIATION 19.7 |
| Sex: Female, Male Female | 30 Participants | 34 Participants | 64 Participants |
| Sex: Female, Male Male | 30 Participants | 25 Participants | 55 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 39 / 60 | 35 / 59 |
| serious Total, serious adverse events | 0 / 60 | 0 / 59 |
Outcome results
Primary
Humoral Immune Response in Terms of Haemagglutination (HA) Antibody Titers Against Each of the Three Vaccine Influenza Strains
Antibody titers were expressed as Geometric mean titers (GMTs). The vaccine strains assessed were Flu A/Christchurch/16/10 (H1N1), Flu A/Victoria/361/11 (H3N2) and Flu B/Hubei-Wujiagang/158/09 (Yamagata).
Time frame: At Day 0 and Day 21
Population: Analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Fluarix/Influsplit 18-60 Years Group | Humoral Immune Response in Terms of Haemagglutination (HA) Antibody Titers Against Each of the Three Vaccine Influenza Strains | H1N1, Day 0 | 20.57 Titer |
| Fluarix/Influsplit 18-60 Years Group | Humoral Immune Response in Terms of Haemagglutination (HA) Antibody Titers Against Each of the Three Vaccine Influenza Strains | H1N1, Day 21 | 366.04 Titer |
| Fluarix/Influsplit 18-60 Years Group | Humoral Immune Response in Terms of Haemagglutination (HA) Antibody Titers Against Each of the Three Vaccine Influenza Strains | H3N2, Day 0 | 16.17 Titer |
| Fluarix/Influsplit 18-60 Years Group | Humoral Immune Response in Terms of Haemagglutination (HA) Antibody Titers Against Each of the Three Vaccine Influenza Strains | H3N2, Day 21 | 93.19 Titer |
| Fluarix/Influsplit 18-60 Years Group | Humoral Immune Response in Terms of Haemagglutination (HA) Antibody Titers Against Each of the Three Vaccine Influenza Strains | Yamagata, Day 0 | 68.60 Titer |
| Fluarix/Influsplit 18-60 Years Group | Humoral Immune Response in Terms of Haemagglutination (HA) Antibody Titers Against Each of the Three Vaccine Influenza Strains | Yamagata, Day 21 | 431.85 Titer |
| Fluarix/Influsplit > 60 Years Group | Humoral Immune Response in Terms of Haemagglutination (HA) Antibody Titers Against Each of the Three Vaccine Influenza Strains | Yamagata, Day 0 | 70.19 Titer |
| Fluarix/Influsplit > 60 Years Group | Humoral Immune Response in Terms of Haemagglutination (HA) Antibody Titers Against Each of the Three Vaccine Influenza Strains | H1N1, Day 0 | 19.02 Titer |
| Fluarix/Influsplit > 60 Years Group | Humoral Immune Response in Terms of Haemagglutination (HA) Antibody Titers Against Each of the Three Vaccine Influenza Strains | H3N2, Day 21 | 65.63 Titer |
| Fluarix/Influsplit > 60 Years Group | Humoral Immune Response in Terms of Haemagglutination (HA) Antibody Titers Against Each of the Three Vaccine Influenza Strains | H1N1, Day 21 | 110.44 Titer |
| Fluarix/Influsplit > 60 Years Group | Humoral Immune Response in Terms of Haemagglutination (HA) Antibody Titers Against Each of the Three Vaccine Influenza Strains | Yamagata, Day 21 | 223.56 Titer |
| Fluarix/Influsplit > 60 Years Group | Humoral Immune Response in Terms of Haemagglutination (HA) Antibody Titers Against Each of the Three Vaccine Influenza Strains | H3N2, Day 0 | 23.90 Titer |
Primary
Mean Geometric Increase (MGI) for Haemagglutination Inhibition (HI) Antibody Titer Against Each of the Three Vaccine Influenza Strains.
MGI was defined as the fold increase in serum HI GMT post-vaccination compared to Day 0.
Time frame: At Day 21
Population: Analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Fluarix/Influsplit 18-60 Years Group | Mean Geometric Increase (MGI) for Haemagglutination Inhibition (HI) Antibody Titer Against Each of the Three Vaccine Influenza Strains. | H1N1 | 17.8 Fold increase |
| Fluarix/Influsplit 18-60 Years Group | Mean Geometric Increase (MGI) for Haemagglutination Inhibition (HI) Antibody Titer Against Each of the Three Vaccine Influenza Strains. | H3N2 | 5.8 Fold increase |
| Fluarix/Influsplit 18-60 Years Group | Mean Geometric Increase (MGI) for Haemagglutination Inhibition (HI) Antibody Titer Against Each of the Three Vaccine Influenza Strains. | Yamagata | 6.3 Fold increase |
| Fluarix/Influsplit > 60 Years Group | Mean Geometric Increase (MGI) for Haemagglutination Inhibition (HI) Antibody Titer Against Each of the Three Vaccine Influenza Strains. | H1N1 | 5.8 Fold increase |
| Fluarix/Influsplit > 60 Years Group | Mean Geometric Increase (MGI) for Haemagglutination Inhibition (HI) Antibody Titer Against Each of the Three Vaccine Influenza Strains. | H3N2 | 2.7 Fold increase |
| Fluarix/Influsplit > 60 Years Group | Mean Geometric Increase (MGI) for Haemagglutination Inhibition (HI) Antibody Titer Against Each of the Three Vaccine Influenza Strains. | Yamagata | 3.2 Fold increase |
Primary
Number of Seroconverted Subjects for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains.
A seroconverted subjects was defined as a vaccinee with either a pre-vaccination titer less than (\<) 1:10 and a post-vaccination titer ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and at least a 4-fold increase in post-vaccination titer.
Time frame: At Day 21
Population: Analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Fluarix/Influsplit 18-60 Years Group | Number of Seroconverted Subjects for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | H1N1 | 45 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Seroconverted Subjects for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | H3N2 | 34 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Seroconverted Subjects for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | Yamagata | 38 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Seroconverted Subjects for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | H1N1 | 34 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Seroconverted Subjects for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | H3N2 | 14 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Seroconverted Subjects for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | Yamagata | 24 Subjects |
Primary
Number of Subjects Who Were Seroprotected for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains.
Seroprotection rate (SPR) was defined as the number of vaccinees with serum haemagglutination inhibition (HI) titer greater than or equal to (≥) 1:40.
Time frame: At Day 0 and Day 21
Population: Analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Who Were Seroprotected for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | H1N1, Day 0 | 20 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Who Were Seroprotected for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | H1N1, Day 21 | 55 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Who Were Seroprotected for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | H3N2, Day 0 | 15 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Who Were Seroprotected for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | H3N2, Day 21 | 51 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Who Were Seroprotected for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | Yamagata, Day 0 | 42 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Who Were Seroprotected for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | Yamagata, Day 21 | 59 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Who Were Seroprotected for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | Yamagata, Day 0 | 51 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Who Were Seroprotected for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | H1N1, Day 0 | 14 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Who Were Seroprotected for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | H3N2, Day 21 | 41 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Who Were Seroprotected for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | H1N1, Day 21 | 47 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Who Were Seroprotected for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | Yamagata, Day 21 | 58 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Who Were Seroprotected for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | H3N2, Day 0 | 23 Subjects |
Primary
Number of Subjects With Seroprotection Power (SPP) for HI Antibody Titer Against Each of the Three Vaccine Influenza Strains Above the Cut-off Value.
SPP was defined as the number of vaccinees with a pre-vaccination titer \< 1:40 and a post-vaccination titer ≥ 1:40.
Time frame: At Day 21
Population: Analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects With Seroprotection Power (SPP) for HI Antibody Titer Against Each of the Three Vaccine Influenza Strains Above the Cut-off Value. | H1N1 [N=39,44] | 35 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects With Seroprotection Power (SPP) for HI Antibody Titer Against Each of the Three Vaccine Influenza Strains Above the Cut-off Value. | H3N2 [N=44,35] | 36 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects With Seroprotection Power (SPP) for HI Antibody Titer Against Each of the Three Vaccine Influenza Strains Above the Cut-off Value. | Yamagata [N=17,7] | 17 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects With Seroprotection Power (SPP) for HI Antibody Titer Against Each of the Three Vaccine Influenza Strains Above the Cut-off Value. | H1N1 [N=39,44] | 33 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects With Seroprotection Power (SPP) for HI Antibody Titer Against Each of the Three Vaccine Influenza Strains Above the Cut-off Value. | H3N2 [N=44,35] | 18 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects With Seroprotection Power (SPP) for HI Antibody Titer Against Each of the Three Vaccine Influenza Strains Above the Cut-off Value. | Yamagata [N=17,7] | 7 Subjects |
Secondary
Duration of Solicited General Symptoms.
Duration was defined as number of days with any grade of general symptoms.
Time frame: During the 4-day follow-up period (Days 0-3) after vaccination
Population: Analysis was performed on the Total Vaccinated cohort, which included all subjects with vaccine administration documented.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Fluarix/Influsplit 18-60 Years Group | Duration of Solicited General Symptoms. | Arthralgia [N=2,4] | 2.5 Days |
| Fluarix/Influsplit 18-60 Years Group | Duration of Solicited General Symptoms. | Fatigue [N=11,14] | 1.0 Days |
| Fluarix/Influsplit 18-60 Years Group | Duration of Solicited General Symptoms. | Gastrointestinal symptoms [N=4,3] | 1.0 Days |
| Fluarix/Influsplit 18-60 Years Group | Duration of Solicited General Symptoms. | Headache [N=15,7] | 1.0 Days |
| Fluarix/Influsplit 18-60 Years Group | Duration of Solicited General Symptoms. | Myalgia [N=11,7] | 1.0 Days |
| Fluarix/Influsplit 18-60 Years Group | Duration of Solicited General Symptoms. | Sweating increase [N=8,9] | 1.0 Days |
| Fluarix/Influsplit 18-60 Years Group | Duration of Solicited General Symptoms. | Shivering [N=1,2] | 1.0 Days |
| Fluarix/Influsplit 18-60 Years Group | Duration of Solicited General Symptoms. | Fever (Axillary) [N=2,1] | 1.0 Days |
| Fluarix/Influsplit > 60 Years Group | Duration of Solicited General Symptoms. | Fever (Axillary) [N=2,1] | 4.0 Days |
| Fluarix/Influsplit > 60 Years Group | Duration of Solicited General Symptoms. | Arthralgia [N=2,4] | 3.0 Days |
| Fluarix/Influsplit > 60 Years Group | Duration of Solicited General Symptoms. | Myalgia [N=11,7] | 1.0 Days |
| Fluarix/Influsplit > 60 Years Group | Duration of Solicited General Symptoms. | Fatigue [N=11,14] | 2.0 Days |
| Fluarix/Influsplit > 60 Years Group | Duration of Solicited General Symptoms. | Shivering [N=1,2] | 1.5 Days |
| Fluarix/Influsplit > 60 Years Group | Duration of Solicited General Symptoms. | Gastrointestinal symptoms [N=4,3] | 1.0 Days |
| Fluarix/Influsplit > 60 Years Group | Duration of Solicited General Symptoms. | Sweating increase [N=8,9] | 2.0 Days |
| Fluarix/Influsplit > 60 Years Group | Duration of Solicited General Symptoms. | Headache [N=15,7] | 1.0 Days |
Secondary
Duration of Solicited Local Symptoms.
Duration was defined as number of days with any grade of local symptoms.
Time frame: During the 4-day follow-up period (Days 0-3) after vaccination
Population: Analysis was performed on the Total Vaccinated cohort, which included all subjects with vaccine administration documented.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Fluarix/Influsplit 18-60 Years Group | Duration of Solicited Local Symptoms. | Induration [N=2,4] | 2.5 Days |
| Fluarix/Influsplit 18-60 Years Group | Duration of Solicited Local Symptoms. | Redness [N=6,7] | 2.5 Days |
| Fluarix/Influsplit 18-60 Years Group | Duration of Solicited Local Symptoms. | Swelling [N=6,5] | 2.0 Days |
| Fluarix/Influsplit 18-60 Years Group | Duration of Solicited Local Symptoms. | Pain [N=33,23] | 2.0 Days |
| Fluarix/Influsplit > 60 Years Group | Duration of Solicited Local Symptoms. | Induration [N=2,4] | 2.0 Days |
| Fluarix/Influsplit > 60 Years Group | Duration of Solicited Local Symptoms. | Pain [N=33,23] | 2.0 Days |
| Fluarix/Influsplit > 60 Years Group | Duration of Solicited Local Symptoms. | Swelling [N=6,5] | 2.0 Days |
| Fluarix/Influsplit > 60 Years Group | Duration of Solicited Local Symptoms. | Redness [N=6,7] | 2.0 Days |
Secondary
Humoral Immune Response in Terms of Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains.
Antibody titers were expressed as Geometric mean titers (GMTs). The vaccine strains included H1N1, H3N2 and Yamagata antigens. The outcome measure was assessed by influenza vaccination status in the 2011-2012 season, in subjects aged greater than (\>) 60 years.
Time frame: At Day 0 and Day 21
Population: Analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Fluarix/Influsplit 18-60 Years Group | Humoral Immune Response in Terms of Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | H1N1, Day 0 | 22.13 Titer |
| Fluarix/Influsplit 18-60 Years Group | Humoral Immune Response in Terms of Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | H1N1, Day 21 | 92.92 Titer |
| Fluarix/Influsplit 18-60 Years Group | Humoral Immune Response in Terms of Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | H3N2, Day 0 | 24.02 Titer |
| Fluarix/Influsplit 18-60 Years Group | Humoral Immune Response in Terms of Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | H3N2, Day 21 | 57.22 Titer |
| Fluarix/Influsplit 18-60 Years Group | Humoral Immune Response in Terms of Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | Yamagata, Day 0 | 77.34 Titer |
| Fluarix/Influsplit 18-60 Years Group | Humoral Immune Response in Terms of Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | Yamagata, Day 21 | 208.70 Titer |
| Fluarix/Influsplit > 60 Years Group | Humoral Immune Response in Terms of Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | Yamagata, Day 0 | 63.26 Titer |
| Fluarix/Influsplit > 60 Years Group | Humoral Immune Response in Terms of Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | H1N1, Day 0 | 16.18 Titer |
| Fluarix/Influsplit > 60 Years Group | Humoral Immune Response in Terms of Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | H3N2, Day 21 | 76.01 Titer |
| Fluarix/Influsplit > 60 Years Group | Humoral Immune Response in Terms of Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | H1N1, Day 21 | 132.89 Titer |
| Fluarix/Influsplit > 60 Years Group | Humoral Immune Response in Terms of Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | Yamagata, Day 21 | 240.65 Titer |
| Fluarix/Influsplit > 60 Years Group | Humoral Immune Response in Terms of Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | H3N2, Day 0 | 23.76 Titer |
Secondary
Mean Geometric Increase (MGI) for Haemagglutination Inhibition (HI) Antibody Titer Against Each of the Three Vaccine Influenza Strains.
MGI was defined as the fold increase in serum HI GMT post-vaccination compared to Day 0. This outcome measure was assessed by influenza vaccination status in the 2011-2012 season, in subjects aged \> 60 years.
Time frame: At Day 21
Population: Analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Fluarix/Influsplit 18-60 Years Group | Mean Geometric Increase (MGI) for Haemagglutination Inhibition (HI) Antibody Titer Against Each of the Three Vaccine Influenza Strains. | H1N1 | 4.2 Fold increase |
| Fluarix/Influsplit 18-60 Years Group | Mean Geometric Increase (MGI) for Haemagglutination Inhibition (HI) Antibody Titer Against Each of the Three Vaccine Influenza Strains. | H3N2 | 2.4 Fold increase |
| Fluarix/Influsplit 18-60 Years Group | Mean Geometric Increase (MGI) for Haemagglutination Inhibition (HI) Antibody Titer Against Each of the Three Vaccine Influenza Strains. | Yamagata | 2.7 Fold increase |
| Fluarix/Influsplit > 60 Years Group | Mean Geometric Increase (MGI) for Haemagglutination Inhibition (HI) Antibody Titer Against Each of the Three Vaccine Influenza Strains. | H1N1 | 8.2 Fold increase |
| Fluarix/Influsplit > 60 Years Group | Mean Geometric Increase (MGI) for Haemagglutination Inhibition (HI) Antibody Titer Against Each of the Three Vaccine Influenza Strains. | H3N2 | 3.2 Fold increase |
| Fluarix/Influsplit > 60 Years Group | Mean Geometric Increase (MGI) for Haemagglutination Inhibition (HI) Antibody Titer Against Each of the Three Vaccine Influenza Strains. | Yamagata | 3.8 Fold increase |
Secondary
Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms.
Solicited local symptoms assessed were ecchymosis, induration, pain, redness and swelling. Any was defined as any solicited local symptom reported irrespective of intensity. Grade 3 pain was defined as pain that prevented normal everyday activities. Grade 3 ecchymosis, induration, redness and swelling was greater than 100 millimeters (mm) i.e. \>100mm.
Time frame: During the 4-day (Day 0-Day 3) follow-up period after vaccination
Population: Analysis was performed on the Total Vaccinated cohort which included all subjects with vaccine administration documented.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms. | Any Ecchymosis | 0 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms. | Grade 3 Ecchymosis | 0 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms. | Any Induration | 2 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms. | Grade 3 Induration | 0 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms. | Any Pain | 33 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms. | Grade 3 Pain | 1 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms. | Any Redness | 6 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms. | Grade 3 Redness | 0 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms. | Any Swelling | 6 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms. | Grade 3 Swelling | 0 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms. | Grade 3 Redness | 0 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms. | Any Ecchymosis | 0 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms. | Grade 3 Pain | 0 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms. | Grade 3 Ecchymosis | 0 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms. | Grade 3 Swelling | 0 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms. | Any Induration | 4 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms. | Any Redness | 7 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms. | Grade 3 Induration | 0 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms. | Any Swelling | 5 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms. | Any Pain | 23 Subjects |
Secondary
Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs)
A serious adverse event was any untoward medical occurrence that: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.
Time frame: During the entire study period (Days 0-21)
Population: Analysis was performed on the Total Vaccinated cohort, which included all subjects with vaccine administration documented.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) | Any SAEs | 0 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) | Related SAEs | 0 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) | Any SAEs | 0 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) | Related SAEs | 0 Subjects |
Secondary
Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms.
Solicited general symptoms assessed were arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, shivering, increased sweating and fever \[axillary temperature above 37.5 degrees Celsius (°C)\]. Gastrointestinal symptoms included nausea, vomiting, diarrhea and/or abdominal pain. Any = any solicited general symptom reported irrespective of intensity and relationship to vaccination. Related = symptoms considered by the investigator to have a causal relationship to vaccination. Grade 3 symptoms = symptoms that prevented normal activity. Grade 3 fever = axillary temperature above 39.0°C
Time frame: During the 4-day follow-up period (Day 0-3) after vaccination
Population: Analysis was performed on the Total Vaccinated cohort, which included all subjects with vaccine administration documented.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Any Gastrointestinal symptoms | 4 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Grade 3 Arthralgia | 0 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Related Arthralgia | 2 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Any Fatigue | 11 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Grade 3 Fatigue | 1 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Related Fatigue | 7 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Any Arthralgia | 2 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Grade 3 Gastrointestinal symptoms | 0 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Related Gastrointestinal symptoms | 2 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Any Headache | 15 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Grade 3 Headache | 1 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Related Headache | 11 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Any Myalgia | 11 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Grade 3 Myalgia | 0 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Related Myalgia | 11 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Any Shivering | 1 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Grade 3 Shivering | 0 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Related Shivering | 1 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Any Sweating increase | 8 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Grade 3 Sweating increase | 0 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Related Sweating increase | 6 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Any Fever ≥37.5°C | 2 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Grade 3 Fever >39.0°C | 0 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Related Fever | 2 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Grade 3 Fever >39.0°C | 0 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Any Arthralgia | 4 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Any Myalgia | 7 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Grade 3 Arthralgia | 0 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Any Sweating increase | 9 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Related Arthralgia | 1 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Grade 3 Myalgia | 0 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Any Fatigue | 14 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Any Fever ≥37.5°C | 1 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Grade 3 Fatigue | 0 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Related Myalgia | 5 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Related Fatigue | 10 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Grade 3 Sweating increase | 0 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Any Gastrointestinal symptoms | 3 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Any Shivering | 2 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Grade 3 Gastrointestinal symptoms | 0 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Related Fever | 1 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Related Gastrointestinal symptoms | 3 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Grade 3 Shivering | 0 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Any Headache | 7 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Related Sweating increase | 6 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Grade 3 Headache | 1 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Related Shivering | 1 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms. | Related Headache | 6 Subjects |
Secondary
Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs).
Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination. Grade 3 was an event that prevented normal activities and related was defined as an unsolicited AE assessed by the investigator to be causally related to the study vaccination.
Time frame: During the 21-day follow-up period (Days 0-20) after vaccination
Population: Analysis was performed on the Total Vaccinated cohort, which included all subjects with vaccine administration documented.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs). | Any Unsolicted AEs | 8 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs). | Grade 3 Unsolicted AEs | 0 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs). | Related Unsolicted AEs | 4 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs). | Any Unsolicted AEs | 11 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs). | Grade 3 Unsolicted AEs | 1 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs). | Related Unsolicted AEs | 3 Subjects |
Secondary
Number of Subjects Who Seroconverted for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains.
SCR was defined as the number of vaccinees with either a pre-vaccination titer less than (\<) 1:10 and a post-vaccination titer ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and at least 4-fold increase in post-vaccination titer. The outcome measure was assessed by influenza vaccination status in the 2011-2012 season, in subjects aged \> 60 years.
Time frame: At Day 21
Population: Analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Who Seroconverted for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | H1N1 | 15 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Who Seroconverted for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | H3N2 | 6 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Who Seroconverted for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | Yamagata | 11 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Who Seroconverted for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | H1N1 | 19 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Who Seroconverted for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | H3N2 | 8 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Who Seroconverted for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | Yamagata | 13 Subjects |
Secondary
Number of Subjects Who Were Seroprotected for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains.
Seroprotection rate SPR was defined as the number of vaccinees with serum haemagglutination inhibition (HI) titer greater than or equal to (≥) 1:40. The outcome measure was assessed by the influenza vaccination status in the 2011-2012 season, in subjects aged \> 60 years.
Time frame: At Day 0 and Day 21
Population: Analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Who Were Seroprotected for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | H1N1, Day 0 | 9 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Who Were Seroprotected for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | H1N1, Day 21 | 24 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Who Were Seroprotected for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | H3N2, Day 0 | 12 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Who Were Seroprotected for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | H3N2, Day 21 | 21 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Who Were Seroprotected for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | Yamagata, Day 0 | 28 Subjects |
| Fluarix/Influsplit 18-60 Years Group | Number of Subjects Who Were Seroprotected for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | Yamagata, Day 21 | 30 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Who Were Seroprotected for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | Yamagata, Day 0 | 23 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Who Were Seroprotected for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | H1N1, Day 0 | 5 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Who Were Seroprotected for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | H3N2, Day 21 | 20 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Who Were Seroprotected for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | H1N1, Day 21 | 23 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Who Were Seroprotected for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | Yamagata, Day 21 | 28 Subjects |
| Fluarix/Influsplit > 60 Years Group | Number of Subjects Who Were Seroprotected for Anti-HA Antibodies Against Each of the Three Vaccine Influenza Strains. | H3N2, Day 0 | 11 Subjects |